News
How Sebasti'n Mesen is advancing a global vision for longevity through regenerative medicine
55+ min ago (847+ words) The global conversation around health is changing. For decades, healthcare systems focused primarily on diagnosing and treating diseases once they appeared. Today, scientific innovation is driving a new vision centered on prevention, regeneration, and long-term health optimization. In this context,…...
Mid-Year Review: What's Trending in New Drug Approvals?
23+ min ago (78+ words) Share Article With Your Colleagues by Email Table 1: Mid-Year Review 2026: New Drug Approvals by FDA's Center for Drug Evaluation and Research (as of July 7, 2026)" One Washington Blvd. , Suite 6 Robbinsville, NJ 08691 USA DCAT Value Chain Insights is produced by the Drug,…...
Astra Zeneca Loses $27 Billion in Market Value After Key Heart Drug Fails Late-Stage Trial
10+ hour, 40+ min ago (272+ words) Astra Zeneca lost $27 billion (KES 3. 5 trillion) in market value after its highly anticipated cardiovascular gene-silencing drug, Wainua, failed a Phase III trial. The late-stage trial enrolled 1, 432 patients worldwide to definitively test Wainua's efficacy. However, the data released on Thursday confirmed…...
A brain-controlled haptic "coach" for safer and smarter rehabilitation
5+ hour, 10+ min ago (452+ words) Researchers have proposed a new rehabilitation design that uses brain signals not to control movement directly, but to decide when and how strongly simple haptic cues should be delivered. Combined with wearable devices based on Mc Kibben artificial muscles, this…...
Canada's Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI" (pegcetacoplan) for the Treatment of C3 G and Primary IC-MPGN
57+ min ago (400+ words) This recommendation represents an important step towards improving access for Canadians living with rare kidney diseases EMPAVELI" is the first treatment authorized in Canada for C3 G or primary IC-MPGN. The positive recommendation from CDA marks an important milestone in the…...
HHS seeks to add COVID-19 countermeasure injuries to federal compensation program
52+ min ago (746+ words) The Health and Human Services (HHS) Department is seeking to add COVID-19 vaccines and therapeutics to a government program that compensates people for injuries or deaths linked to the administration of medical countermeasures recommended by the agency during public health…...
Phase 3 Failure Keeps Astra Zeneca and Ionis Out of a Growing Heart Disease Market
46+ min ago (295+ words) Astra Zeneca and Ionis Pharmaceuticals drug eplontersen, brand name Wainua, failed a Phase 3 test in cardiomyopathy caused by transthyretin amyloidosis. More details will be shared at a medical conference next month, but it appears the RNA therapy's slim hopes now…...
New Anti-Aging Therapy Shows 70% Improvement, But There's a Crucial Detail the Headlines Aren't Telling You
1+ hour, 31+ min ago (702+ words) Headlines screaming about 70% lifespan extensions from breakthrough biotech treatments have flooded news feeds recently. The science behind these claims tells a dramatically different story. While the underlying biology remains genuinely fascinating, experts warn that marketing claims have raced far ahead…...
XLV Waters Down Massive Growth From GLP-1 Obesity Drug Leaders
4+ hour, 54+ min ago (342+ words) The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) remains the default allocation for millions of investors seeking exposure to insurers, medical device makers, biotechnology, and big pharma companies. As reported by Detik Finance, XLV has returned 21. 61% over the past year…...
Medical-Commercial alignment in rare disease launches: what breaks first?
7+ hour, 37+ min ago (650+ words) Alignment is a cultural output, not a process input The strongest view in the room was that launch excellence frameworks do not create genuine Medical-Commercial alignment. Alignment must originate from within leadership culture. When teams are measured on activity but…...